In addition to this treatments, the targeted radioligand therapy (RLT) that specifically targets prostate specific membrane antigen (PSMA) has proven to be a promising approach for reducing total tumor burden and improving survival 10-12. The gene discussed is FOLH1; the disease is neoplasm.